Clinical trials
catalyst calendar across sponsors →Studies where IMMX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., Qube Research & Technologies Ltd, +4 more) · FINRA short interest 5.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid TumorsNCT05840835Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0Open-label · Treatment | Phase 1/2 | Unknown status | Drug: IMX-110 combined with Tislelizumab | Advanced Solid Tumor | 60 | 2024-01-24 | 2023-08-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19